Cochlear Ltd
ASX:COH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
249.78
319.63
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
COH
stock under the Base Case scenario is
229.43
AUD.
Compared to the current market price of 258.7 AUD,
Cochlear Ltd
is
Overvalued by 11%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Cochlear Ltd.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Regulatory and reimbursement constraints in key markets, especially the U.S. and Europe, could weaken Cochlear's pricing power, threatening the profitability of its high-end implants.
Intensifying competition from rivals like Sonova (Advanced Bionics) and MED-EL may pressure Cochlear to increase R&D spend and discount pricing, shrinking operating margins.
Reliance on complex electronic components and a specialized supply chain leaves the firm vulnerable to component shortages or production delays that could hamper timely product rollouts.
Cochlear's clear global leadership and strong brand reputation in implantable hearing solutions position it to capture growing demand, particularly among aging populations with hearing loss.
Expansion into emerging markets, coupled with an extensive service and support network, can fuel international growth and offset potential slowdowns in established regions.
A robust R&D pipeline targeting enhanced sound processing and smartphone connectivity may sustain Cochlear's technological edge, driving continued premium pricing and adoption.
Revenue & Expenses Breakdown
Cochlear Ltd
Balance Sheet Decomposition
Cochlear Ltd
| Current Assets | 1.4B |
| Cash & Short-Term Investments | 275.7m |
| Receivables | 597.7m |
| Other Current Assets | 543.4m |
| Non-Current Assets | 1.4B |
| Long-Term Investments | 189.4m |
| PP&E | 536.2m |
| Intangibles | 500.8m |
| Other Non-Current Assets | 181.8m |
| Current Liabilities | 602.3m |
| Accounts Payable | 298.4m |
| Accrued Liabilities | 113.4m |
| Other Current Liabilities | 190.5m |
| Non-Current Liabilities | 272.4m |
| Long-Term Debt | 193.5m |
| Other Non-Current Liabilities | 78.9m |
Free Cash Flow Analysis
Cochlear Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Cochlear Ltd
|
Revenue
|
2.3B
AUD
|
|
Cost of Revenue
|
-605.6m
AUD
|
|
Gross Profit
|
1.7B
AUD
|
|
Operating Expenses
|
-1.2B
AUD
|
|
Operating Income
|
532.5m
AUD
|
|
Other Expenses
|
-143.6m
AUD
|
|
Net Income
|
388.9m
AUD
|
COH Profitability Score
Profitability Due Diligence
Cochlear Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Cochlear Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
COH Solvency Score
Solvency Due Diligence
Cochlear Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Cochlear Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
COH Price Targets Summary
Cochlear Ltd
According to Wall Street analysts, the average 1-year price target for
COH
is 314.06 AUD
with a low forecast of 281.3 AUD and a high forecast of 373.8 AUD.
Dividends
Current shareholder yield for
COH is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
COH
stock under the Base Case scenario is
229.43
AUD.
Compared to the current market price of 258.7 AUD,
Cochlear Ltd
is
Overvalued by 11%.